5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as a third-line chemotherapy treatment in metastatic gastric cancer, after failure of fluoropyrimidine, platinum, anthracycline, and taxane

摘要: Studies on the effects of third-line chemotherapy (CT) in advanced gastric cancer (GC) patients are still scarce. The aim this study was to evaluate efficacy and safety modified 5-fluorouracil, leucovorin, irinotecan (mFOLFIRI) regimen as a CT metastatic GC patients, after failure fluoropyrimidine, platinum, anthracycline, taxane. After first- second-line therapies, 42 received FOLFIRI (180 mg/m² 400 leucovorin administered concomitantly 90-minute intravenous (IV) infusion day 1, followed by 5-fluorouracil IV bolus then 2600 continuous over 46 hours), between January 2009 December 2015. for median 6 cycles (range 4-12 cycles). Eight achieved partial response, while 13 showed stable disease, resulting overall response rate (ORR) 19% disease control (DCR) 50%. most frequent grade 3-4 hematological non-hematological toxicities were neutropenia (14.2%) diarrhea (7.1%). progression-free survival (PFS) (OS) from start 3.8 months (95% confidence interval [CI], 3.0-4.5) 6.8 CI, 5.6-7.9), respectively. According multivariate analysis, two factors independently predictive poor OS: >2 regions metastasis (relative risk [RR], 2.6; 95% 1.3-5.4) high level carcinoembryonic antigen [CEA] (RR, 3.4; 1.6-7.4). In conclusion, well tolerated promising PFS OS